—Key Findings Include the Need for Patient Customization Options and
Improved Procedures for Return of Clinical Trial Medications—
(TAMPA, FLORIDA, USA, 04 November 2013) – ISPE today released the first report on its project concerning patient experiences with clinical trial materials. The report details the results of the Society’s patient survey, which measured the experiences of 1,425 respondents in the industry’s first large-scale effort to collect data of this kind from patients engaged in clinical trials. The report was released today at the 2013 ISPE Annual Meeting, during an executive session on ISPE Research Initiatives, and it was made possible through the underwriting support of eleven companies engaged in studies involving IMPs.
The survey collected a robust set of data related to patients’ current and recent experiences, attitudes and perceptions, suggestions for improvements and demographic information. Among the survey’s key findings were:
The ISPE Patient Survey Project Team will continue to review and analyze the survey data in the coming months. The team currently plans to present additional findings throughout 2014 and to engage both industry leaders and regulators in a series of discussions to plan follow up projects. These “phase II” investigations will expand on the current data set and further investigate the themes above—as well as others which may yet be revealed.
ISPE, the International Society for Pharmaceutical Engineering, is the world’s largest not-for-profit association serving its Members through leading scientific, technical and regulatory advancement throughout the pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions in the development and manufacture of safe and effective pharmaceutical and biologic medicines and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters in Tampa, Florida, USA. Visit www.ISPE.org for more information.